The vaccine development program of AFFiRiS is based on the company's AFFITOME(R) technology, which also delivered the vaccines tested so far. Also based on this technology are six other vaccination programs being developed by AFFiRiS AG, which target, among other indications, Parkinson's disease and atherosclerosis.
About AFFiRiS AG (status November 2009):
Based on proprietary patent positions, AFFiRiS has developed tailored peptide vaccines against Alzheimer's Disease, Parkinson's and four other diseases characterized by urgent medical requirement and attractive market volumes. Alzheimer's is the current lead indication and clinical Phase I trials have just been completed on two product candidates. AFFiRiS succeeded in attracting GlaxoSmithKline Biologicals as its licensing partner in October 2008. The contract contains provisions for (milestone-dependent) payments of up to EUR 430 million. Based on the successful completion of two clinical Phase I trials, a payment of EUR 10 million was made in October. AFFiRiS currently employs 60 highly-qualified staff at its premises on the St. Marx Campus in Vienna, Austria (http://www.affiris.com).
Contact AFFiRiS AG: Mag. Agnes Meyer Karl-Farkas-Gasse 22 T +43-1-798-15-75-3 mailto:firstname.lastname@example.org '/>"/>
|SOURCE AFFiRiS AG|
Copyright©2009 PR Newswire.
All rights reserved